It is made available under a CC-BY 4.0 International license .

1	Bone canonical Wnt signaling is downregulated in type 2 diabetes and
2	associates with higher Advanced Glycation End-products (AGEs) content and
3	reduced bone strength
4	
5	Giulia Leanza MSc, PhD ^{1,2} , Francesca Cannata MSc, PhD ¹ , Malak Faraj MSc ¹ , Claudio Pedone
6	MD, PhD ³ , Viola Viola MSc ¹ , Flavia Tramontana MSc, PhD ^{1,2} , Niccolò Pellegrini MSc ¹ ,
7	Gianluca Vadalà, MD, PhD ⁴ , Alessandra Piccoli PhD ¹ , Rocky Strollo MD, PhD ⁵ , Francesca
8	Zalfa, MSc, PhD ^{6,7} , Alec Beeve PhD ⁸ , Erica L Scheller DDS, PhD ⁸ , Simon Tang PhD ⁹ , Roberto
9	Civitelli MD ⁸ , Mauro Maccarrone PhD ^{10,11} , Rocco Papalia MD, PhD ^{4,*+} and Nicola Napoli MD,
10	PhD ^{1,2,8*†}
11	
12	¹ Department of Medicine and Surgery, Research Unit of Endocrinology and Diabetes,
13	Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy;
14	² Operative Research Unit of Osteometabolic and Thyroid Diseases, Fondazione Policlinico
15	Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200–00128, Roma, Italy;
16	³ Operative Research Unit of Geriatrics, Fondazione Policlinico Universitario Campus Bio-
17	Medico, Via Alvaro del Portillo, 200–00128, Roma, Italy;
18	⁴ Operative Research Unit of Orthopedic and Trauma Surgery, Fondazione Policlinico
19	Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200–00128, Roma, Italy;
20	⁵ Department of Human Sciences and Promotion of the Quality of Life San Raffaele Roma Open
21	University Via di Val Cannuta 247, 00166 Roma, Italy
22	⁶ Predictive Molecular Diagnostic Unit, Pathology Department, Fondazione Policlinico
23	Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200–00128, Roma, Italy;
24	⁷ Microscopic and Ultrastructural Anatomy Unit, Università Campus Bio-Medico di Roma, Via
25	Alvaro del Portillo 21, 00128 Roma, Italy
26	⁸ Department of Medicine, Division of Bone and Mineral Diseases. Musculoskeletal Research
27	Center, Washington University School of Medicine, St. Louis, MO USA;
28	⁹ Department of Orthopaedic Surgery, Washington University in St. Louis, St. Louis, MO, USA;
29	¹⁰ Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via
30	Vetoio snc, 67100 L'Aquila, Italy;

It is made available under a CC-BY 4.0 International license .

31 32 33	¹¹ European Center for Brain Research, Santa Lucia Foundation IRCCS, 00164 Roma, Italy
34 35	+ These authors are equally senior authors.
36	*Corresponding Authors:
37	Nicola Napoli, MD PhD
38	Department of Medicine and Surgery
39	Research Unit of Endocrinology and Diabetes
40	Università Campus Bio-Medico di Roma
41	Via Alvaro del Portillo 21
42	00128 Roma, Italy
43	n.napoli@unicampus.it
44	
45	Rocco Papalia, MD PhD
46	Operative Research Unit of Orthopedic and Trauma Surgery
47	Fondazione Policlinico Campus Bio-Medico di Roma
48	Via Alvaro del Portillo 200
49	00128 Roma, Italy
50	r.papalia@fondazionepoliclinico.it
51	
52	Short title: Wnt signaling in bone of type 2 diabetes
53	
54	Keywords: Diabetes, Bone, Wnt signaling, AGEs
55	
56	Disclosures
57	All authors have nothing to disclose relevant to this work.
-0	
58	

It is made available under a CC-BY 4.0 International license .

60 Abstract

Type 2 diabetes (T2D) is associated with higher fracture risk, despite normal or high bone mineral 61 62 density. We reported that bone formation genes (SOST and RUNX2) and Advanced Glycation Endproducts (AGEs) were impaired in T2D. We investigated Wnt signaling regulation and its 63 association with AGEs accumulation and bone strength in T2D from bone tissue of 15 T2D and 64 65 21 non-diabetic postmenopausal women undergoing hip arthroplasty. Bone histomorphometry revealed a trend of low mineralized volume in T2D [(T2D 0.249% (0.156-0.366) vs non-diabetic 66 subjects 0.352% (0.269-0.454); p=0.053)], as well as reduced bone strength [T2D 21.60 MPa 67 (13.46-30.10) vs non-diabetic subjects 76.24 MPa (26.81-132.9); p=0.002]. We also showed that 68 69 gene expression of Wnt agonists *LEF-1* (p=0.0136) and *WNT10B* (p=0.0302) were lower in T2D. Conversely, gene expression of WNT5A (p=0.0232), SOST (p<0.0001) and GSK3B (p=0.0456) 70 were higher, while collagen (COL1A1) was lower in T2D (p=0.0482). AGEs content was 71 72 associated with SOST and WNT5A (r=0.9231, p<0.0001; r=0.6751, p=0.0322), but inversely 73 correlated with *LEF-1* and *COL1A1* (r= -0,7500, p=0.0255; r= -0,9762, p=0.0004). SOST was associated with glycemic control and disease duration (r=0.4846, p=0.0043; r=0.7107, 74 p=0.00174), whereas WNT5A and GSK3B were only correlated with glycemic control (r=0.5589, 75 76 p=0.0037; r=0.4901, p=0.0051). Finally, Young's Modulus was negatively correlated with SOST (r=-0.5675, p=0.0011), AXIN2 (r=-0.5523, p=0.0042) and SFRP5 (r=-0.4442, p=0.0437), while77 positively correlated with LEF -1 (r=0.4116, p=0.0295) and WNT10B (r=0.6697, p=0.0001). These 78 findings suggest that Wnt signaling, and AGEs could be the main determinants of bone fragility 79 80 in T2D.

81

It is made available under a CC-BY 4.0 International license .

Graphical abstract



It is made available under a CC-BY 4.0 International license .

94 Introduction

95 Type 2 diabetes (T2D) is a metabolic disease, with an increasing worldwide prevalence,

96 characterized by chronic hyperglycemia and adverse effects on multiple organ systems, including bones [1]. Patients with T2D have an increased fracture risk, particularly at the hip, compared to 97 individuals without diabetes. A recent meta-analysis reported that individuals with T2D have 98 99 1.27 relative risk (RR) of hip fracture compared to non-diabetic controls [2]. Fragility fractures in patients with T2D occur at normal or even higher bone mineral density compared to healthy 100 subjects, implying compromised bone quality in diabetes. T2D is associated with a reduced bone 101 turnover [3], as shown by lower serum levels of biochemical markers of bone formation, such as 102 103 procollagen type1 amino-terminal propeptide (P1NP) and osteocalcin, and bone resorption, Cterminal cross-linked telopeptide (CTX) in diabetic patients compared to nondiabetic individuals 104 [4-7]. Accordingly, dynamic bone histomorphometry of T2D postmenopausal women showed a 105 lower bone formation rate, mineralizing surface, osteoid surface, and osteoblast surface[8]. Our 106 107 group recently demonstrated that T2D is also associated with increased SOST and decreased RUNX2 genes expression, compared to non-diabetic subjects[9]. Moreover, we have proved in a 108 diabetic model that a sclerostin-resistant Lrp5 mutation, associated with high bone mass, fully 109 protected bone mass and strength even after prolonged hyperglycemia [10]. Sclerostin is a potent 110 inhibitor of the canonical Wnt signaling pathway, a key pathway that regulates bone homeostasis 111 112 [11].

Diabetes and chronic hyperglycemia are also characterized by increased advanced glycation endproducts (AGEs) production and deposition [12]. AGEs may interfere with osteoblast
differentiation, attachment to the bone matrix, function, and survival [13,14]. AGEs also alter
bone collagen structure and reduce the intrinsic toughness of bone, thereby affecting bone

It is made available under a CC-BY 4.0 International license .

117 material properties [9,15,16]. In this work, we hypothesized that T2D and AGEs accumulation

118 downregulate Wnt canonical signaling and negatively affect bone strength.. Results confirmed

that T2D downregulates Wnt beta/catenin signaling and reduces collagen mRNA levels and bone

- 120 strength, in association with AGEs accumulation.
- 121

122 Materials and Methods

123 Study subjects

We enrolled a total of 36 postmenopausal women (15 with T2D and 21 non-diabetic controls)

undergoing hip arthroplasty for osteoarthritis, consecutively screened to participate in this study

between 2020 and 2022. Diabetes status was confirmed by the treating diabetes physician.

127 Participants were diagnosed with diabetes when they had fasting plasma glucose (FPG) ≥ 126

128 mg/dl or 2-h plasma glucose (2-h PG) ≥200 mg/dl during a 75-g oral glucose tolerance test

129 (OGTT); or hemoglobin A1c (HbA1c) $\geq 6.5\%$ in accordance with the American Diabetes

130 Association diagnostic criteria. Eligible participants were ≥ 60 years of age. Exclusion criteria

131 were any diseases affecting bone or malignancy. Additionally, individuals treated with

132 medications affecting bone metabolism such as estrogen, raloxifene, tamoxifen,

133 bisphosphonates, teriparatide, denosumab, thiazolidinediones, glucocorticoids, anabolic steroids,

and phenytoin, and those with hypercalcemia or hypocalcemia, hepatic or renal disorder,

135 hypercortisolism, current alcohol or tobacco use were excluded. The study was approved by the

136 Ethics Committee of the Campus Bio-Medico University of Rome and all participants provided

137 written informed consent. All procedures were conducted in accordance with the Declaration of

138 Helsinki.

It is made available under a CC-BY 4.0 International license .

140 Specimen preparation

141 Femoral head specimens were obtained during hip arthroplasty. As described previously [9],

trabecular bone specimens were collected fresh and washed multiple times in sterile PBS until

143 the supernatant was clear of blood. Bone samples were stored at -80 °C until analysis.

144 Bone histomorphometry

145 Trabecular bone from femur heads werefixed in 10% neutral buffered formalin for 24 h prior to 146 storage in 70% ethanol. Tissues were embedded in methylmethacrylate and sectioned sagittally 147 by the Washington University Musculoskeletal Histology and Morphometry Core. Sections were stained with Goldner's trichrome. Then, a rectangular region of interest containing trabecular 148 149 bone was chosen below the cartilage-lined joint surface and primary spongiosa. This region had an average dimension of 45 mm². Tissue processing artifacts, such as folding and edges, were 150 151 excluded from the ROI. A threshold was chosen using the Bioquant Osteo software to 152 automatically select trabeculae and measure bone volume. Finally, Osteoid was highlighted in 153 the software and quantified semi-automatically using a threshold and correcting with the brush tool. Unstained and TRAP-stained (Sigma) slides were imaged at ×20 high resolution using a 154 155 NanoZoomer 2.0 with bright field and FITC/TRITC (Hamamatsu Photonics). Images were then analyzed via Bioquant Osteo software according to the manufacturer's instructions and published 156 standards (v18.2.6, Bioquant Image Analysis Corp., Nashville, TN). 157

158 Bone compression tests

159 We used cylindrical bone specimens of trabecular core (with a diameter of 10 mm and a length

160 of 20 mm) from 10 T2D and 21 non-diabetic subjects to measure bone mechanical parameters

161 (Young's modulus, ultimate strength and yield strength), as previously described [9].

It is made available under a CC-BY 4.0 International license .

162 RNA extraction and gene expression by RT-PCR

Total RNA from trabecular bone samples was extracted using TRIzol (Invitrogen) following the 163 164 manufacturer's instructions. The concentration and purity of the extracted RNA were assessed spectrophotometrically (TECAN, InfiniteM200PRO), and only samples with 260/280 absorbance 165 ratio between 1.8 and 2 were used for reverse transcription using High-Capacity cDNA Reverse 166 167 Transcription Kit (Applied Biosystems, Carlsbad, CA) according to the manufacturer's recommendations. Transcription products were amplified using TaqMan real-time PCR (Applied 168 Biosystems, Carlsbad, CA) and a standard protocol (95°C for 10 minutes; 40 cycles of 95°C for 169 15 seconds and 60°C for 1 minute; followed by 95°C for 15 seconds, 60°C for 15 seconds, and 170 171 95°C for 15 seconds). β-Actin expression was used as an internal control (housekeeping gene). Relative expression levels of Sclerostin (SOST), Dickkopf-1 (DKK-1), Wnt ligands (WNT5A and 172 WNT10B), T-cell factor/ lymphoid enhancer factor 1 (LEF-1), collagen type I alpha 1 chain 173 (COL1A1), glycogen synthase kinase 3 beta (GSK3B), axis inhibition protein 2 (AXIN2), beta-174 175 catenin (BETA-CATENIN) and secreted frizzled-related protein 5 (SFRP5) were calculated using the $2^{-\Delta Ct}$ method. 176

177 Statistical analysis

Data were analyzed using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA). Patients' characteristics were described using means and standard deviations or medians and 25th-75th percentiles, as appropriate, and percentages. Group data are presented in boxplots with median and interquartile range; whiskers represent maximum and minimum values. We assessed data for normality and Mann-Whitney test was used to compare variables between groups. Data were analyzed using nonparametric Spearman correlation analysis and the correlation coefficients (r)

It is made available under a CC-BY 4.0 International license .

were used to assess the relationship between variables. We used Grubbs' Test to assess andexclude outliers.

186 **RESULTS**

187 Subject characteristics

188 Clinical characteristics of study subjects are presented in Table 1. T2D and non-diabetic subjects

189 did not differ in age, BMI and menopausal age. As expected, fasting glucose was significantly

higher in T2D compared to non-diabetic subjects [112.00 mg/dl (104.0-130.0) mg/dl, vs. 94.00

191 (87.2-106.3), respectively; p=0.009]. Median HbA1c was determined in all T2D subjects within

three months before surgery [(6.95% (6.37-7.37)]. Median disease duration in T2D subjects was

193 [14.50 years (7.25-19.25)]. Diabetes medications included monotherapy with metformin (n=12)

and combination therapy with metformin plus insulin and glinide (n=3). There were no

195 differences in serum calcium, eGFR (CKD-EPI equation) and serum blood urea nitrogen.

196 Bone Histomorphometry

- 197 Bone samples of 8 T2D and 9 non-diabetic subjects were used for histomorphometry analysis.
- 198 We found no significant differences in BV/TV and osteoid volume, while mineralized

volume/total volume (Md.V/TV) trended lower in T2D subjects relative to controls [0.249%

200 (0.156-0.336) vs 0.352% (0.269-0.454); p=0.053] (Table 2).

201 Bone compression tests

202 Young's modulus was lower in T2D compared to non-diabetic subjects [21.6 MPa (13.46-30.10)

vs. 76.24 MPa (26.81-132.9); p=0.0025), while ultimate strength and yield strength were not

204 different between the two groups (Table 3).

It is made available under a CC-BY 4.0 International license .

205 Gene Expression

- 206 SOST mRNA was significantly higher in T2D than in non-diabetic subjects (Fig. 1A, p<0.0001),
- whereas there was no difference in *DKK1* gene expression between the two groups (Fig. 1B). Of
- 208 note, SOST mRNA transcript was very low in the majority of non-diabetic subjects (Fig. 1A).
- 209 *LEF-1* (Fig. 1C, p=0.0136), *WNT10B* (*Fig. 1D*, p=0.0302) and *COL1A1* (Fig.1F, p=0.0482)
- 210 mRNA transcripts were significantly lower in T2D compared to non-diabetic subjects.
- 211 Conversely, WNT5A was higher in T2D relative to non-diabetics (Fig. 1E, p=0.0232). Moreover,
- 212 GSK3B was significantly increased in T2D compared to non- diabetic subjects (Fig.1G,
- p=0.0456), but we did not find any significant difference in gene expression of AXIN2, BETA-
- 214 *CATENIN* and *SFRP5* (Fig. 1H-J) between our groups.

215 Correlation analysis of Wnt target genes, AGEs and glycemic control

As shown in figure 2, AGEs were inversely correlated with LEF-1 (Fig. 2A, p=0.0255) and 216 COL1A1 mRNA abundance (Fig. 2B, p=0.0004), whereas they were positively correlated with 217 SOST (Fig. 2C, p<0.0001) and WNT5A mRNA (Fig. 2D, p=0.0322). There was no correlation 218 between AGEs content and WNT10B (Fig. 2E; p=0.1938) or DKK1 gene expression (Fig. 2F; 219 p=0.9349). Likewise, we did not find any significant correlation between LEF-1. WNT5A. 220 WNT10B, DKK-1, COL1A1 expression in bone and glycemic control in T2D individuals 221 (Supplemental Figure 1A-D). However, there were positive correlations between SOST and fasting 222 223 glucose levels (Fig. 3A, p=0.0043), SOST and disease duration (Fig. 3B, p=0.00174), WNT5A, GSK3B and fasting glucose levels (Fig. 3C, p=0.0037; Fig. 3D, p=0.0051). 224

225

It is made available under a CC-BY 4.0 International license .

227 Correlation analysis of Wnt target genes and bone mechanical parameters

As shown in Figure 4, Young's Modulus was negatively correlated with SOST (Fig.4A, p=0.0011), 228 229 AXIN2 (Fig. 4D, p=0.0042) and SFRP5 (Fig 4F, p=0.0437), while positively correlated with LEF 230 -1 (Fig. 4B, p=0.0295) and WNT10B (Fig. 4C, p=0.0001). Ultimate strength was associated with WNT10B (Fig. 4F, p=0.0054) and negatively correlated with AXIN2 (Fig. 4G, p=0.0472). Finally, 231 232 yield strength was associated with LEF-1 (Fig. 4H, p=0.0495) and WNT10B (Fig. 4I, p=0.0020) and negatively correlated with GSK3B (Fig. 4J, p=0.0245), AXIN2 (Fig. 4K, p=0.0319), and 233 SFRP5 (Fig. 4L, p=0.0422). Non-significant correlations are reported in Supplementary figure 2 234 (A-Q). 235

236 Discussion

237 We show that key components of the Wnt/beta-catenin signaling are abnormally expressed in the 238 bone of postmenopausal women with T2D and they are associated with AGEs and reduced bone strength. *LEF-1*, a transcription factor that mediates responses to Wnt signal and Wnt target 239 genes itself, and WNT10B, an endogenous regulator of Wnt/ β -catenin signaling and skeletal 240 progenitor cell fate, are both downregulated in bone of postmenopausal women with T2D. 241 242 Consistently, in this group, the expression of the Wnt inhibitor, SOST is increased, suggesting 243 suppression of Wnt/ β -catenin signaling. Interestingly, our data suggest that sclerostin expression is very low in healthy postmenopausal women not affected by osteoporosis. Moreover, we 244 245 reported an increase in the expression level of bone GSK3B, in line with downregulated Wnt/ β catenin signaling in T2D. Our data also show that the expression of WNT5A, a non-canonical 246 ligand linked to inhibition of Wnt/beta-catenin signaling was increased, whereas COL1A1 was 247 decreased. These findings are consistent with reduced bone formation and suppression of Wnt 248 249 signaling in T2D. We have previously reported upregulation of SOST and downregulation of

It is made available under a CC-BY 4.0 International license .

RUNX2 mRNA in another cohort of postmenopausal women with T2D [9]. Of note, the cohort of 250 251 T2D subjects studied here had glycated hemoglobin within therapeutic targets, implying that the 252 changes in gene transcription we identified persist in T2D bone despite good glycemic control. 253 High circulating sclerostin has been reported in diabetes [17,18], and increased sclerostin is associated with fragility fractures [19]. Aside from confirming higher SOST expression, we also 254 255 show that other Wnt/β-catenin osteogenic ligands are abnormally regulated in the bone of T2D postmenopausal women. WNT10B is a positive regulator of bone mass; transgenic 256 overexpression in mice results in increased bone mass and strength [20], whereas genetic 257 ablation of WNT10B is characterized by reduced bone mass [21,22], and decreased number and 258 259 function of osteoblasts [21]. More to the point, WNT10B expression is reduced in the bone of diabetic mice [23]. Therefore, the reduced WNT10B in human bone we found in the present 260 study further supports the hypothesis of reduced bone formation in T2D. Accordingly, LEF-1 261 262 gene expression was also downregulated confirming that Wnt/beta-catenin pathway is decreased 263 in T2D. Importantly, the overexpression of *LEF-1* induces the expression of osteoblast differentiation genes (osteocalcin and COL1A1) in differentiating osteoblasts [24]. In fact, in this 264 265 study we also demonstrated that a downregulation of LEF-1 in T2D bone goes along with a 266 downregulation of *COL1A1*, strengthen data of a reduced production of bone matrix most likely as the result of reduced osteoblasts synthetic activity in diabetes [8.25]. Reduced RUNX2 in 267 T2D postmenopausal women also confirms previous findings [9] and further supports the notion 268 of reduced osteoblast differentiation or function in diabetes. On the other hand, the contribution 269 270 of upregulated WNT5A in diabetic bone is more complex. WNT5A regulates Wnt/beta-catenin signaling depending on the receptor availability [26]. Non-canonical WNT5A activates β-catenin-271 independent signaling, including the Wnt/Ca⁺⁺ [27] and planar cell polarity pathways [28]. 272

It is made available under a CC-BY 4.0 International license .

Heterozygous Wnt5a null mice have low bone mass with impaired osteoblast and osteoclast 273 274 differentiation [29]. Wnt5a inhibits Wnt3a protein by downregulating beta/catenin-induced 275 reporter gene expression [26]. In line with these findings, we showed that there was an increased gene expression of WNT5A in bone of T2D postmenopausal women, confirming a 276 downregulated Wnt/beta-catenin signaling and impaired osteoblasts function. Moreover, GSK3B 277 278 is a widely expressed serine/threonine kinase involved in multiple pathways regulating immune 279 cell activation and glucose metabolism. Preclinical studies reported that GSK3B is a negative regulator of Wnt/beta-catenin signaling and bone metabolism [30,31], and its increase is 280 associated with T2D and alterations in insulin secretion and sensitivity [32,33]. Our data, 281 282 confirmed that GSK3B is increased in T2D postmenopausal women and it is associated with reduced yield strength. In fact, we also showed an impaired bone mechanical plasticity in T2D, 283 in line with other studies showing a reduced bone strength [16,34,35]. In addition, this study 284 reported significant correlations of bone mechanical parameters and Wnt target genes, which 285 286 might reflect the biological effect of downregulated Wnt signaling and AGEs accumulation on bone mechanical properties in diabetes. 287

288 We have previously shown that AGEs content is higher in T2D bone compared to non-diabetic bone, even in patients with well-controlled T2D [9]. Here we show that AGEs accumulation is 289 positively correlated with SOST, WNT5A and GSK3B gene expression, and negatively correlated 290 291 with *LEF-1*, *WNT10B*, and *COL1A1* mRNA. These findings are consistent with the hypothesis that AGEs accumulation is associated with impaired Wnt signaling and low bone turnover in 292 293 T2D. We did not find any abnormalities in histomorphometric parameters in our subjects with 294 T2D, consistent with our previous report [9]. Reduced osteoid thickness and osteoblast number were reported in premenopausal T2D women with poor glycemic control compared to non-295

It is made available under a CC-BY 4.0 International license .

diabetic subjects but not in the group with good glycemic control [36]. Therefore, good
glycemic control appears to prevent or rescue any changes in static histologic parameters of bone
turnover that might be caused by uncontrolled diabetes.

299 Our study has some limitations. One is the cross-sectional design; another one is the relatively

small number of T2D subjects enrolled. Moreover, we measured the mRNA abundance of the

301 genes of interest, and we cannot assume that the differences we found reflect differences in

302 protein abundance. Although osteoarthritis may affect some of the genes we studied [37], all

303 study subjects were affected by variable degree of osteoarthritis, and the effect of such potential

304 confounder is not likely to be different between T2D and control subjects. Finally, we did not use

305 the tetracycline double-labeled technique to investigate dynamic bone parameters.

The main strength of our study is that this study is the first to explore the association of AGEs on
Wnt pathway in postmenopausal T2D women. Moreover, we measured the expression of several
Wnt genes directly on bone samples of postmenopausal T2D women.

In conclusion, our data show that, despite good glycemic control, T2D decreases expression of *COL1A1* and Wnt genes that regulate bone turnover, in association with increased AGEs content and reduced bone strength. These results may help understand the mechanisms underlying bone fragility in T2D.

313

314

315

316

It is made available under a CC-BY 4.0 International license .

317 Acknowledgements

318 This work was supported by an internal Grant of Campus Bio-Medico University of Rome.

319

320

321	Author Contributions: Conceptualization, N.N, R.P., M.M and R.S.; methodology, G.L., F.C.,
322	M.F., V.V., F.T., N.P., A.B., S.T; software, G.L., C.P., A.B., and E.S.; validation, N.N. and
323	G.L.; formal analysis, N.N. and G.L.; investigation, N.N., R.S., M.M. and R.P.; resources, N.N,
324	G.V., R.P. M.M., and R.S.; data curation, G.L. and N.P; writing-original draft preparation,
325	G.L., M.F., N.P., R.C. and N.N.; writing-review and editing, G.L., N.N., C.P., N.P., F.Z., E.S.,
326	R.S. and R.C.; visualization, N.N. and R.S; supervision, N.N., R.P., and M.M.; project
327	administration, N.N. and G.L.; funding acquisition, N.N. and R.S. All authors have read and
328	agreed to the published version of the manuscript.
329	
330	
331	
332	
333	
334	
335	

It is made available under a CC-BY 4.0 International license .

337 **References**

338	[1]	Hofbauer LC, Busse B, Eastell R, Ferrari S, Frost M, Müller R, et al. Bone fragility in
339		diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol
340		2022;10:207-20. https://doi.org/10.1016/S2213-8587(21)00347-8.
341	[2]	Wang H, Ba Y, Xing Q, Du J-L. Diabetes mellitus and the risk of fractures at specific
342		sites: a meta-analysis. BMJ Open 2019;9:e024067. https://doi.org/10.1136/bmjopen-2018-
343		024067.
344	[3]	Rubin MR, Patsch JM. Assessment of bone turnover and bone quality in type 2 diabetic
345		bone disease: current concepts and future directions. Bone Res 2016;4:16001.
346		https://doi.org/10.1038/boneres.2016.1.
347	[4]	Napoli N, Strollo R, Defeudis G, Leto G, Moretti C, Zampetti S, et al. Serum Sclerostin
348		and Bone Turnover in Latent Autoimmune Diabetes in Adults. J Clin Endocrinol Metab
349		2018;103:1921-8. https://doi.org/10.1210/jc.2017-02274.
350	[5]	Hygum K, Starup-Linde J, Harsløf T, Vestergaard P, Langdahl BL. MECHANISMS IN
351		ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic
352		review and meta-analysis. Eur J Endocrinol 2017;176:R137-57.
353		https://doi.org/10.1530/EJE-16-0652.
354	[6]	Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus -
355		A systematic review. Bone 2016;82:69-78. https://doi.org/10.1016/j.bone.2015.02.019.
356	[7]	Starup-Linde J, Lykkeboe S, Gregersen S, Hauge E-M, Langdahl BL, Handberg A, et al.
357		Differences in biochemical bone markers by diabetes type and the impact of glucose.

It is made available under a CC-BY 4.0 International license .

358 Bone 2016;83:149–55. https://doi.org/1	10.1016/j.bone.2015.11.004.
--	-----------------------------

- 359 [8] Manavalan JS, Cremers S, Dempster DW, Zhou H, Dworakowski E, Kode A, et al.
- 360 Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab
- 361 2012;97:3240–50. https://doi.org/10.1210/jc.2012-1546.
- 362 [9] Piccoli A, Cannata F, Strollo R, Pedone C, Leanza G, Russo F, et al. Sclerostin
- 363 Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of
- Elderly Women With Type 2 Diabetes. J Bone Miner Res 2020;35:2415–22.
- 365 https://doi.org/10.1002/jbmr.4153.
- 366 [10] Leanza G, Fontana F, Lee S-Y, Remedi MS, Schott C, Ferron M, et al. Gain-of-Function
- 367 Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse

368 Model of Insulin-Deficient Diabetes. J Bone Miner Res 2021;36:1403–15.

369 https://doi.org/10.1002/jbmr.4303.

- 370 [11] Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, et al. The
- Regulation of Bone Metabolism and Disorders by Wnt Signaling. Int J Mol Sci 2019;20.
- 372 https://doi.org/10.3390/ijms20225525.
- 373 [12] Tan KCB, Chow W-S, Ai VHG, Metz C, Bucala R, Lam KSL. Advanced glycation end
- products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002;25:1055–9.
- 375 https://doi.org/10.2337/diacare.25.6.1055.
- 376 [13] Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, et al. Advanced glycation
- end-products attenuate human mesenchymal stem cells and prevent cognate differentiation
- into adipose tissue, cartilage, and bone. J Bone Miner Res 2005;20:1647–58.
- 379 https://doi.org/10.1359/JBMR.050514.

It is made available under a	CC-BY 4.0 International license	е
------------------------------	---------------------------------	---

- 380 [14] Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human
- 381 osteoblasts in vitro. Ann N Y Acad Sci 2008;1126:166–72.
- 382 https://doi.org/10.1196/annals.1433.044.
- 383 [15] Yamamoto M, Sugimoto T. Advanced Glycation End Products, Diabetes, and Bone
- 384 Strength. Curr Osteoporos Rep 2016;14:320–6. https://doi.org/10.1007/s11914-016-0332-
- 385

1.

- 386 [16] Furst JR, Bandeira LC, Fan W-W, Agarwal S, Nishiyama KK, McMahon DJ, et al.
- 387 Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. J Clin
- 388 Endocrinol Metab 2016;101:2502–10. https://doi.org/10.1210/jc.2016-1437.
- 389 [17] García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana
- B, García-Salcedo JA, et al. Circulating levels of sclerostin are increased in patients with

type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:234–41.

- 392 https://doi.org/10.1210/jc.2011-2186.
- 393 [18] Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, et al. Circulating
- sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab
 2012;97:1737–44. https://doi.org/10.1210/jc.2011-2958.
- 396 [19] Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with
- 397 vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab
- 398 2013;98:4030–7. https://doi.org/10.1210/jc.2013-2143.
- 399 [20] Longo KA, Wright WS, Kang S, Gerin I, Chiang S-H, Lucas PC, et al. Wnt10b inhibits
- 400 development of white and brown adipose tissues. J Biol Chem 2004;279:35503–9.
- 401 https://doi.org/10.1074/jbc.M402937200.

It is made available under a CC-BY 4.0 International license .

- 402 [21] Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, et al. Regulation
- 403 of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A
- 404 2005;102:3324–9. https://doi.org/10.1073/pnas.0408742102.
- 405 [22] Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner
- 406 Metab 2009;27:265–71. https://doi.org/10.1007/s00774-009-0064-8.
- 407 [23] Zhang J, Motyl KJ, Irwin R, MacDougald OA, Britton RA, McCabe LR. Loss of Bone
- 408 and Wnt10b Expression in Male Type 1 Diabetic Mice Is Blocked by the Probiotic
- 409 Lactobacillus reuteri. Endocrinology 2015;156:3169–82.
- 410 https://doi.org/10.1210/EN.2015-1308.
- 411 [24] Hoeppner LH, Secreto F, Jensen ED, Li X, Kahler RA, Westendorf JJ. Runx2 and bone
- 412 morphogenic protein 2 regulate the expression of an alternative Lef1 transcript during
- 413 osteoblast maturation. J Cell Physiol 2009;221:480–9. https://doi.org/10.1002/jcp.21879.
- 414 [25] Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, et al.
- 415 Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse
- 416 Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1
- 417 as a Potential Target for Reversing Diabetes-Induced Osteopenia. Diabetes 2015;64:2609–
- 418 23. https://doi.org/10.2337/db14-1611.
- 419 [26] Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF
- 420 signaling depending on receptor context. PLoS Biol 2006;4:e115.
- 421 https://doi.org/10.1371/journal.pbio.0040115.
- 422 [27] Dejmek J, Säfholm A, Kamp Nielsen C, Andersson T, Leandersson K. Wnt-5a/Ca2+-
- 423 induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha

It is made available under a CC-BY 4.0 International license .

- 424 signaling in human mammary epithelial cells. Mol Cell Biol 2006;26:6024–36.
- 425 https://doi.org/10.1128/MCB.02354-05.
- 426 [28] Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, et al. The receptor tyrosine
- 427 kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells
- 428 2003;8:645–54. https://doi.org/10.1046/j.1365-2443.2003.00662.x.
- 429 [29] Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, et al. Wnt5a-
- 430 Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances
- 431 osteoclastogenesis. Nat Med 2012;18:405–12. https://doi.org/10.1038/nm.2653.
- 432 [30] McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, et al. Role that
- phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis.

434 EMBO J 2005;24:1571–83. https://doi.org/10.1038/sj.emboj.7600633.

- 435 [31] Chen Y, Chen L, Huang R, Yang W, Chen S, Lin K, et al. Investigation for GSK3β
- 436 expression in diabetic osteoporosis and negative osteogenic effects of GSK3 β on bone
- 437 marrow mesenchymal stem cells under a high glucose microenvironment. Biochem
- 438 Biophys Res Commun 2021;534:727–33. https://doi.org/10.1016/j.bbrc.2020.11.010.
- 439 [32] Nunez Lopez YO, Iliuk A, Petrilli AM, Glass C, Casu A, Pratley RE. Proteomics and
- 440 Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into
- 441 Diabetes Pathobiology. Int J Mol Sci 2022;23. https://doi.org/10.3390/ijms23105779.
- Xia H, Scholtes C, Dufour CR, Ouellet C, Ghahremani M, Giguère V. Insulin action and
 resistance are dependent on a GSK3β-FBXW7-ERRα transcriptional axis. Nat Commun
 2022;13:2105. https://doi.org/10.1038/s41467-022-29722-6.

It is made available under a CC-BY 4.0 International license .

445	[34]	Farr JN.	Drake MT.	Amin S. Meltor	n L.J. McCready	v LK. Khosla S	S. In vivo assessment of

- bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res
- 447 2014;29:787–95. https://doi.org/10.1002/jbmr.2106.
- 448 [35] Hunt HB, Torres AM, Palomino PM, Marty E, Saiyed R, Cohn M, et al. Altered Tissue
- 449 Composition, Microarchitecture, and Mechanical Performance in Cancellous Bone From
- 450 Men With Type 2 Diabetes Mellitus. J Bone Miner Res 2019;34:1191–206.
- 451 https://doi.org/10.1002/jbmr.3711.
- 452 [36] Andrade VFC, Chula DC, Sabbag FP, Cavalheiro DD da S, Bavia L, Ambrósio AR, et al.
- Bone Histomorphometry in Young Patients With Type 2 Diabetes is Affected by Disease
- 454 Control and Chronic Complications. J Clin Endocrinol Metab 2020;105.
- 455 https://doi.org/10.1210/clinem/dgz070.
- 456 [37] Weivoda MM, Youssef SJ, Oursler MJ. Sclerostin expression and functions beyond the
- 457 osteocyte. Bone 2017;96:45–50. https://doi.org/10.1016/j.bone.2016.11.024.
- 458
- 459
- 460
- 461
- 462
- 463

It is made available under a CC-BY 4.0 International license .

Table 1. Clinical features of the study subjects

	T2D subjects	Non-diabetic	P value
	(n=15)	subjects	
		(n=21)	
Age (years)	73.00 (67.00-80.00)	73.00 (68.50-79.00)	0.644
BMI (kg/m²)	30.81 (24.44-34.00)	25.00 (24.00-31.50)	0.117
Menopausal age (years)	50.00 (42.50-52.75)	52.00 (48.00-53.00)	0.344
Fasting glucose levels (mg/dl)	112.00 (104.00-130.0)	94.00 (87.25-106.3)	**0.009
Disease duration (years)	14.50 (7.25-19.25)	-	-
HbA1c (%)	6.95 (6.37-7.37)	-	-
Serum calcium (mg/dl)	9.05 (8.800-9.550)	9.15 (9.000-9.550)	0.535
eGFR (mL/min/1.73 m²)	78,30 (59.90-91.10)	75.60 (61.35-88.55)	0.356
Serum blood urea nitrogen (mg/dl)	42.00 (36.00-53.00)	37.00 (31.75-46.50)	0.235

Table 1. Results were analyzed using unpaired T-test with Welch's correction. Results are

468 presented as median and percentiles (25th and 75th).

It is made available under a CC-BY 4.0 International license .

	T2D subjects	Non-diabetic	P value
	(n=8)	subjects	
		(n=9)	
BV/TV (%)	0.248 (0.358 (0.271-	0.120
	0.157-0.407)	0.456)	
Md.V/BV (%)	0.994(0.984-	0.995 (0.985-	0.998
	0.998)	0.997)	
Md.V/TV (%)	0.249 (0.156-	0.352 (0.269-	0.053
	0.366)	0.454)	
OV/BV (%)	0.009 (0.002- 0.009)	0.004 (0.002- 0.015)	0.704
OV/TV (%)	0.001 (0.0002- 0.0058)	0.001 (0.0007- 0.0056)	0.896
OS/BS (%)	0.026 (0.022-	0.035 (0.009-	0.525
	0.161)	0.117)	

Table 2. Histomorphometric parameters of trabecular bone of the study subjects

473

Table 2. Results were analyzed using unpaired T-test with Welch's correction and are presented

as median and percentiles (25th and 75th).

It is made available under a CC-BY 4.0 International license .

	T2D subjects	Non-diabetic	P value
	(n=10)	subjects	
		(n=21)	
Young's modulus (MPa)	21.60 (13.46-	76.24 (26.81-	0.002
	30.10)	132.9)	
Ultimate strength (MPa)	3.015 (2.150-	7.240 (3.150-	0.914
	13,86)	8.898)	
Yield strength (MPa)	2.525 (1.943-	6.150 (3.115-	0.159
	6.393)	7.423)	

Table 3. Bone mechanical parameters of trabecular bone of the study subjects

479 Table 3. Results were analyzed using unpaired T-test with Welch's correction and are presented480 as median and percentiles (25th and 75th).

It is made available under a CC-BY 4.0 International license .

486 Figure 1.



It is made available under a CC-BY 4.0 International license .

Figure 2. 504

505



It is made available under a CC-BY 4.0 International license .

508 **Figure 3.**



It is made available under a CC-BY 4.0 International license .

Figure 4. 519



521

It is made available under a CC-BY 4.0 International license .

523 Figure Legends

Figure 1. Gene expression analysis in trabecular bone samples. (A) SOST mRNA levels resulted 524 525 higher in T2D subjects versus Nondiabetic subjects (p<0.0001). (B) DKK-1 mRNA expression level was not different between groups (p=0.2022). (C) LEF-1 mRNA levels resulted lower in 526 527 T2D subjects versus nondiabetics subjects (p=0.0136). (D) WNT10B mRNA expression level 528 was lower in T2D subjects versus nondiabetic subjects (p=0.0302). (E) WNT5A mRNA resulted higher in T2D subjects versus nondiabetics subjects (p=0.0232). (F) COL1A1 mRNA levels 529 resulted lower in T2D subjects versus Nondiabetic subjects (p=0.0482). (G) GSK3B mRNA 530 levels resulted higher in T2D subjects versus Nondiabetic subjects (p=0.0456). (H-J) AXIN2, 531 532 BETA-CATENIN, SFRP5 mRNA levels were not different between groups (p=0.2296, 533 p=0.3073; p=0.1390). Data are expressed as fold changes over beta-actinMedians and 534 interquartile ranges, differences between non-diabetics and T2D subjects were analyzed using Mann-Whitney test. 535

536 Figure 2. Relationship between AGEs (µg quinine/g collagen) bone content and mRNA level of

the Wnt signaling key genes in T2D and non-diabetic subjects. (A) LEF-1 negatively correlated

with AGEs (r=-0.7500; p=0.0255). (B) COL1A1 negatively correlated with AGEs (r=-0.9762;

p=0.0004). (C) SOST mRNA level expression positively correlated with AGEs (r=0.9231;

540 p<0.0001). (D) WNT5A mRNA expression level positively correlated with AGEs (r=0.6751;

541 p=0.0322). (E) WNT10B mRNA expression level was not correlated with AGEs (r=-0.4883;

542 p=0.1938). (F) DKK1 mRNA expression level was not correlated with AGEs (r=0.0476;

543 p=0.9349). (G) GSK3B mRNA expression level was positively correlated with AGEs (r=0.7500;

544 p=0.0255). (H) SFRP5 mRNA expression level was positively correlated with AGEs (r=0.7167;

545 p=0.0369). (I) AXIN2 and (J) SFRP5 mRNA expression levels were not correlated with AGEs

It is made available under a CC-BY 4.0 International license .

546 (r=0.5500, p=0.1328; r=0.2167, p=0.5809). Data were analyzed using nonparametric Spearman
547 correlation analysis and r represents the correlation coefficient.

548 Figure 3. Relationship between fasting glucose levels (mg/dl) and disease duration with SOST

and WNT5A mRNA levels. (A) SOST positively correlated with fasting glucose levels

550 (r=0.4846; p=0.0043). (B) SOST positively correlated with disease duration (r=0.7107;

p=0.0174). (C) WNT5A positively correlated with fasting glucose levels (r=0.5589; p=0.0037).

(D) GSK3B positively correlated with fasting glucose levels (r=0.4901; p=0.0051). Data were

analyzed using nonparametric Spearman correlation analysis and r represents the correlation

554 coefficient.

555 Figure 4. Relationship between Young Modulus (MPa), Ultimate strength (MPa) and Yield

strength (MPa) with mRNA levels of the Wnt signaling key genes in T2D and non-diabetic

subjects. (A) SOST negatively correlated with Young Modulus (MPa); (r=-0.5675; p=0.0011).

(B) LEF-1 positively correlated with Young Modulus (MPa); (r=0.4116; p=0.0295). (C)

559 WNT10B positively correlated with Young Modulus (MPa); (r=0.6697; p=0.0001). (D) AXIN2

negatively correlated with Young Modulus (MPa); (r=-0.5523; p=0.0042). (E) BETA-CATENIN

negatively correlated with Young Modulus (MPa); (r=-0.5244; p=0.0050). (F) SFRP5 negatively

correlated with Young Modulus (MPa); (r=-0.4442; p=0.0437). (G) WNT10B positively

correlated with Ultimate strength (MPa); (r=0.5392; p=0.0054). (H) AXIN2 negatively

correlated with Ultimate strength (MPa); (r=-0.4180; p=0.0472). (I) BETA-CATENIN

negatively correlated with Ultimate strength (MPa); (r=-0.5528; p=0.0034). (J) LEF-1 positively

566 correlated with Yield strength (MPa); (r=0.4338; p=0.0495). (K) WNT10B positively correlated

567 with Yield strength (MPa); (r=0.6632; p=0.0020). (L) GSK3B negatively correlated with Yield

strength (MPa); (r=-0.4674; p=0.0245). (M) AXIN2 negatively correlated with Yield strength

It is made available under a CC-BY 4.0 International license .

569 (MPa); (r=-0.5067; p=0.0319). (N) BETA-CATENIN negatively correlated with Yield strength

570 (MPa); (r=-0.5491; p=0.0149). (O) SFRP5 negatively correlated with Yield strength (MPa); (r=-

- 571 0.5357; p=0.0422). Data were analyzed using nonparametric Spearman correlation analysis and r
- 572 represents the correlation coefficient.
- 573

574 Supplementary figure 1.



586

It is made available under a CC-BY 4.0 International license .

588 Supplementary figure 2.



It is made available under a CC-BY 4.0 International license .

606 Legend of supplementary figures

- 607 Supplementary figure 1. Relationship between fasting glucose levels (mg/dl) and LEF-1,
- 608 WNT5A, WNT10B, DKK-1, COL1A1 mRNA levels. (A-E) Data showed negative correlations
- between fasting glucose levels (mg/dl) and (A) LEF-1 (r=-0.3649; p=0.0613), (B) WNT10B (r=-
- 610 0.0041; p=0.9863), (C) COL1A1 (r=-0.1157; p=0.5354), (D) DKK-1 (r=-0.0947; p=0.6522)
- 611 mRNA levels. Data showed positive correlations between fasting glucose levels (mg/dl) with (E)
- 612 AXIN2 (r=0.0993; p=0.6442), (F) BETA-CATENIN (r=0.2371; p=0.1991) and (G) SFRP5
- 613 (r=0.3767; p=0.0696). Data were analyzed using nonparametric Spearman correlation analysis
- and r represents the correlation coefficient.
- 615 **Supplementary figure 2**. Relationship between Young Modulus (MPa), Ultimate strength
- 616 (MPa) and Yield strength (MPa) with mRNA levels of the Wnt signaling genes in T2D and non-
- 617 diabetic subjects. (A) DKK-1 positively correlated with Young Modulus (MPa); (r=0.02857;
- 618 p=0.9022). (B) COL1A1 positively correlated with Young Modulus (MPa); (r=0.2991;
- 619 p=0.1397). (C) GSK3B negatively correlated with Young Modulus (MPa); (r=-0.3127;
- 620 p=0.0814). (D) SOST negatively correlated with Ultimate strength (MPa); (r=-0.1468;
- 621 p=0.4001). (E) DKK-1 negatively correlated with Ultimate strength (MPa); (r=0.1353;
- p=0.5694). (F) LEF-1 positively correlated with Ultimate strength (MPa); (r=0.2790; p=0.1588).
- 623 (G) WNT5A negatively correlated with Ultimate strength (MPa); (r=-0.0143; p=0.9469). (H)
- 624 COL1A1 positively correlated with Ultimate strength (MPa); (r=0.2138; p=0.3047). (I) GSK3B
- negatively correlated with Ultimate strength (MPa); (r=-0.3482; p=0.0594). (J) SFPR5
- 626 negatively correlated with Ultimate strength (MPa); (r=-0.3789; p=0.0994). (K) SOST positively
- 627 correlated with Yield strength (MPa); (r=0.1009; p=0.6390). (L) DKK-1 positively correlated
- 628 with Yield strength (MPa); (r=0.2786; p=0.3139). (M) WNT10B negatively correlated with

It is made available under a CC-BY 4.0 International license .

629	Yield strength (MPa); (r=-0.0079; p=0.9744). (N) COL1A1 positively correlated with Yield
630	strength (MPa); (r=0.2196; p=0.3260). (O) BETA-CATENIN negatively correlated with Young
631	Modulus strength (MPa); (r=-0.1667; p=0.4953). (P) BETA-CATENIN negatively correlated
632	with Ultimate strength (MPa); (r=-0.2797; p=0.2610). (Q) BETA-CATENIN negatively
633	correlated with Yield strength (MPa); (r=-0.1813; p=0.5537). Data were analyzed using
634	nonparametric Spearman correlation analysis and r represents the correlation coefficient.
635	
636	
637	
638	
639	
640	
641	
642	
643	
644	
645	
646	







